Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SHE:300204)
China
· Delayed Price · Currency is CNY 36.85
+2.35 (6.81%)
Jun 13, 2025, 2:45 PM CST
SHE:300204 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | -146.3 | -147.73 | -398.89 | -197.01 | -137.4 | -133.02 | Upgrade
|
| Depreciation & Amortization | 22.35 | 22.35 | 32.31 | 33.99 | 36.8 | 34.87 | Upgrade
|
| Other Amortization | 0.51 | 0.51 | 0.14 | 0.07 | 0.12 | 0.22 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.28 | -0.28 | -0.3 | 0.04 | - | -2.23 | Upgrade
|
| Asset Writedown & Restructuring Costs | -0.01 | -0.01 | 10.55 | 25.36 | 3.52 | -0.23 | Upgrade
|
| Loss (Gain) From Sale of Investments | -0.14 | -0.14 | 0 | -4.05 | -20.82 | -16.35 | Upgrade
|
| Other Operating Activities | 0.72 | 0.39 | 1.17 | 0.36 | 0.65 | 0.84 | Upgrade
|
| Change in Accounts Receivable | 27.62 | 27.62 | 126.6 | -83.75 | -148.12 | -9.18 | Upgrade
|
| Change in Inventory | -1.25 | -1.25 | -11.99 | 5.85 | 8.28 | 13 | Upgrade
|
| Change in Accounts Payable | -78.56 | -78.56 | -20.3 | 89.63 | 170.49 | 36.56 | Upgrade
|
| Operating Cash Flow | -61.92 | -63.68 | -228.32 | -175.6 | -162.07 | -114.6 | Upgrade
|
| Capital Expenditures | -20.72 | -23.53 | -32.15 | -56.51 | -56.24 | -48.86 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.1 | 0.17 | 0.24 | 0.01 | 0.01 | 5.67 | Upgrade
|
| Investment in Securities | 30.65 | 27.57 | 49.75 | 371.25 | 175.86 | -118.22 | Upgrade
|
| Other Investing Activities | 0 | - | - | 6.57 | 23.02 | 21.12 | Upgrade
|
| Investing Cash Flow | 10.03 | 4.21 | 17.84 | 321.32 | 142.66 | -140.29 | Upgrade
|
| Short-Term Debt Issued | - | 46.36 | 60.14 | 22.94 | - | 53.52 | Upgrade
|
| Total Debt Issued | 66.36 | 46.36 | 60.14 | 22.94 | - | 53.52 | Upgrade
|
| Short-Term Debt Repaid | - | -45.16 | -42.69 | -0.67 | -48 | -5.52 | Upgrade
|
| Long-Term Debt Repaid | - | -0.06 | -0.47 | -2.62 | -2.5 | - | Upgrade
|
| Total Debt Repaid | -75.22 | -45.22 | -43.16 | -3.3 | -50.5 | -5.52 | Upgrade
|
| Net Debt Issued (Repaid) | -8.86 | 1.14 | 16.98 | 19.65 | -50.5 | 48 | Upgrade
|
| Issuance of Common Stock | 66.9 | 26.9 | 14.68 | 16.37 | 18.31 | - | Upgrade
|
| Common Dividends Paid | -0.29 | -0.54 | -1.02 | - | -0.32 | -0.85 | Upgrade
|
| Other Financing Activities | 19.94 | - | - | -3.4 | -3.4 | -3.4 | Upgrade
|
| Financing Cash Flow | 77.69 | 27.5 | 30.64 | 32.62 | -35.91 | 43.75 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.3 | 0.34 | 0.03 | 1.64 | -0.24 | -0.89 | Upgrade
|
| Net Cash Flow | 26.1 | -31.63 | -179.81 | 179.98 | -55.56 | -212.04 | Upgrade
|
| Free Cash Flow | -82.64 | -87.21 | -260.47 | -232.12 | -218.31 | -163.46 | Upgrade
|
| Free Cash Flow Margin | -28.20% | -26.85% | -71.52% | -42.28% | -37.36% | -38.44% | Upgrade
|
| Free Cash Flow Per Share | -0.17 | -0.18 | -0.55 | -0.48 | -0.46 | -0.34 | Upgrade
|
| Cash Income Tax Paid | 20.3 | 18.11 | 17.88 | 31.18 | 41.33 | 41.28 | Upgrade
|
| Levered Free Cash Flow | -51.19 | -54.17 | -159.59 | -190.16 | -150.29 | -94.67 | Upgrade
|
| Unlevered Free Cash Flow | -50.67 | -53.77 | -158.86 | -189.93 | -149.88 | -94.03 | Upgrade
|
| Change in Net Working Capital | 23.8 | 25.25 | -71.59 | 30.48 | 7.01 | -32.39 | Upgrade
|
Updated Oct 24, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.